Blogs - ��Ҵ�ý

��ٱ��䷡-��®: A New Standard for Genome-Wide DNA Break Characterization in Gene Editing

Jamie Harmes — Tue, 10 Mar 2026 10:53:28 +0000

��ٱ��䷡-��®: A New Standard for Genome-Wide DNA Break Characterisation in Gene Editing

Gene editing safety is ultimately a question of DNA break behaviour.

Where do breaks occur?
How often do they occur?
Under what conditions do they persist or resolve?
And can those events be measured reproducibly in the cell types that matter?

As gene editing technologies move from research settings toward clinical translation, answering these questions with precision is no longer optional. It’s foundational.

Despite the rapid evolution of CRISPR-Cas systems, base editors, and prime editors, the tools used to characterise off-target activity have not always kept pace. Many widely adopted methods rely on indirect readouts, PCR-amplified libraries, or fragmented multi-assay workflows. Others measure the final genomic outcome long after editing has occurred, rather than capturing the break event itself.

The consequence is familiar to many teams: incomplete visibility, ambiguous interpretation, and difficulty standardising data across discovery, optimisation, and IND-enabling studies.

��ٱ��䷡-��® has been developed to address this gap directly.

Why direct DNA break characterization matters

Nuclease-based gene editing systems are designed to introduce targeted DNA damage at specific genomic loci. However, no editing system operates with perfect specificity. In addition to the intended on-target modification, unintended off-target activity can occur across the genome.

For nuclease-based systems, these events often manifest as double-strand breaks (DSBs), which represent a significant genotoxic risk. Off-target DNA breaks can lead to large-scale genomic rearrangements, activation of oncogenes, disruption of tumour suppressor genes, and other adverse outcomes.

Importantly, even newer approaches such as base editing and prime editing, often positioned as avoiding DSBs—have been shown to induce DNA breaks and other forms of genotoxicity under certain conditions.

As regulatory expectations evolve, empirical, genome-wide evidence of editing activity is increasingly required. Regulatory agencies including the FDA and EMA now expect unbiased, genome-wide characterisation in clinically relevant cell types, rather than reliance solely on in silico or in vitro approaches.

There is also a clear shift toward earlier assessment during discovery, enabling teams to eliminate suboptimal candidates before significant time and cost are invested.

Despite this, many programmes still lack a scalable, sensitive, cell-based method capable of directly measuring both on-target and off-target DNA break activity early enough to influence decision-making.

A different approach: capturing breaks at their point of occurrence

��ٱ��䷡-��® is a scalable, genome-wide, in cellulo platform for the direct detection and quantification of DNA breaks.

Rather than extracting genomic DNA first and labelling break ends later, ��ٱ��䷡-��® performs in situ break labelling within fixed and permeabilised cells. This preserves the genomic context of break events as they existed inside the cell and avoids distortions introduced by post-extraction manipulation and PCR amplification.

Each break end is directly labelled with sequencing adapters, enabling sequencing to initiate from the break itself. Because the workflow is PCR-free, each sequencing read corresponds to a single captured break event, providing a quantitative and unbiased representation of DNA break frequency.

This PCR-free design is central to quantitative confidence, particularly when measuring low-frequency off-target events.

From break labelling to sequencing

Following in situ labelling, genomic DNA is extracted and mechanically fragmented to generate sequencing-compatible fragments. A partially functional sequencing adapter is ligated to fragmented ends, creating a selective library architecture.

Only fragments that carry both the break-labelled adapter and the complementary sequencing adapter form functional constructs capable of binding to the sequencing flow cell. Unlabelled genomic fragments are rendered non-functional.

This selective library design enriches specifically for break-labelled fragments, dramatically improving sensitivity while reducing the sequencing depth required to detect rare events.

The output is genome-wide, single-nucleotide resolution mapping of DNA breaks across the entire genome.

Integrated bioinformatics for decision-ready outputs

Sequencing data generated by ��ٱ��䷡-��® are processed through an integrated bioinformatics platform purpose-built for genome-wide break mapping.

Reads are mapped to the reference genome, break sites are resolved at base-level precision, and candidate on- and off-target sites are identified through a dual analytical framework combining frequency-based and homology-based analysis.

This approach enables:

Quantitative assessment of break frequency (enabled by PCR-free design)
Cross-referencing with predicted cleavage sites
Nomination and ranking of candidate off-target sites based on evidence of nuclease-induced activity

Each candidate site is assigned a probability score reflecting the likelihood of true induction versus background noise.

Outputs are delivered through structured, interpretable reports, including nomination tables, break site plots, mismatch plots, and supporting datasets suitable for both discovery optimisation and regulatory documentation.

The emphasis is not simply on detection, but on clarity, prioritisation, and decision-making.

What ��ٱ��䷡-��® delivers

At its core, ��ٱ��䷡-��® provides:

Genome-wide, single-nucleotide resolution mapping of DNA breaks
Simultaneous characterisation of on-target and off-target activity within a single workflow
Measurement of both induced and endogenous background DNA breaks
Compatibility with major gene editing systems, including CRISPR, TALENs, Zinc-Fingers, as well as base and prime editing
Broad applicability across primary cells, stem cells, T cells, iPSCs, and immortalised cell lines
A standardised, in-house workflow capable of delivering results within days

Running the platform in-house ensures full control of data, auditability, and programme confidentiality—an increasingly important consideration as programmes move toward regulatory submission.

Applications across the gene editing pipeline

One of the strengths of ��ٱ��䷡-��® is its flexibility across development stages.

Discovery
��ٱ��䷡-��® enables rapid, side-by-side comparison of guide RNAs, nuclease variants, and editing conditions, generating full on- and off-target profiles to support early candidate selection and programme de-risking.

Lead characterisation and optimisation
By sampling multiple timepoints post-editing, teams can capture break formation and repair dynamics, providing insight into editing kinetics, nuclease behaviour, and cell-type specific responses. These data inform optimisation strategies, delivery approaches, and nuclease engineering decisions.

Translational and IND-enabling studies
Regulatory expectations increasingly require unbiased, genome-wide data generated in clinically relevant systems using well-characterised methods. ��ٱ��䷡-��® provides reproducible, standardised outputs suitable for inclusion in IND data packages, with clear structure and traceability.

Across each stage, the workflow remains consistent, reducing variability and enabling continuity from discovery through to clinical translation.

Raising the standard for break analysis

As gene editing technologies become more powerful, the standard for genomic safety assessment rises alongside them.

Empirical, genome-wide evidence of editing activity is no longer a late-stage requirement—it is an expectation throughout development.

��ٱ��䷡-��® addresses this need by directly capturing DNA breaks at their point of formation, within intact cells, without PCR amplification. The result is quantitative precision, single-nucleotide resolution, and an integrated analytical framework that translates complex sequencing data into clear, decision-ready outputs.

For gene editing teams seeking to de-risk programmes, accelerate iteration cycles, and build robust datasets aligned with modern regulatory expectations, ��ٱ��䷡-��® represents a shift from indirect inference to direct measurement.

And in genome editing, direct measurement is what ultimately builds confidence.

Learn more

Permalink

Solving the Off-Target Analysis Bottleneck: Decision-Focused Bioinformatics for Gene Editing

Jamie Harmes — Tue, 28 May 2019 09:27:55 +0000

Gene editing programs no longer struggle to generate data. They struggle to interpret it.

Genome-wide off-target mapping technologies have advanced rapidly in recent years. It’s now routine to generate hundreds to thousands of putative off-target sites from a single experiment. Detection sensitivity has improved. Sequencing costs have fallen. Throughput has increased. Yet the critical question remains surprisingly difficult to answer: Which of these sites matter?

As editing programs move from early discovery toward IND-enabling studies, the pressure shifts from identifying events to discriminating between them. The challenge is no longer technical detection. It’s decision clarity.

The hidden fragmentation in off-target analysis

Across the industry, wet-lab technologies and bioinformatics workflows are often developed in parallel rather than in partnership. A laboratory assay may be robust and reproducible, but the downstream analysis pipeline frequently relies on adapted academic tools, custom scripts, or loosely maintained research software.

This separation creates friction. Analytical assumptions may not fully reflect the chemistry of the assay. Updates to one side of the workflow are not always mirrored on the other. As programs scale, these small disconnects compound.

In early research environments this may be manageable. In translational or regulated settings, it becomes a risk.

Bioinformatics tools used for off-target assessment often originate in academic groups where innovation is prioritised over long-term maintenance. They can be powerful in expert hands, but they are rarely built for cross-functional biotech teams working under timeline pressure. Documentation may be light. Compute requirements may be heavy. Reproducibility between operators may depend on specialist knowledge.

None of this is inherently flawed. But it is not optimised for industrial development.

When outputs don’t drive action

Most pipelines focus on identifying and reporting putative off-target sites. They generate extensive tables of genomic positions, event` counts, and statistical values. For data scientists, this level of detail is necessary. For programme leaders, however, it can obscure the central question: what should we prioritise next?

A list of thousands of detected sites does not equate to a prioritised off-target profile. Without structured ranking, replicate-aware filtering, and treated-versus-control normalisation, interpretation becomes manual and iterative. Weeks can be spent moving from raw output to a defensible shortlist of candidate sites.

At scale, this slows experimental cycles and introduces subjective interpretation. The bottleneck is not sequencing depth. It is analytical discrimination.

Moving from detection to discrimination

As gene editing technologies mature, analytical expectations must mature with them. A robust off-target workflow should not simply catalogue genome-wide breaks. It should distinguish likely editor-induced events from endogenous background noise and low-confidence signals, using quantitative and statistical frameworks that are transparent and reproducible. This requires bioinformatics that is deliberately designed around the assay generating the data.

��ٱ��䷡-��® Analysis: tightly coupled assay and analysis

��ٱ��䷡-��® Analysis was developed alongside the ��ٱ��䷡-��® wet lab assay with that principle in mind. Rather than adapting a generic sequencing pipeline, the analytical framework was designed specifically for PCR-free double-strand break mapping at genome scale.

The workflow begins with rigorous read processing. FASTQ files undergo quality assessment and trimming before alignment to the selected reference genome. Break positions are resolved at base-level precision and merged across replicates to generate proportional genome-wide break counts. The output is not simply mapped reads, but a quantitative representation of break frequency across the genome.

Each detected break site is then annotated in biological context. Intersection with genes and repeat regions is assessed, reproducibility across replicates is evaluated, and proximity to guide-like sequences is considered where relevant. This contextual layer allows interpretation to move beyond position alone.

Crucially, break sites detected in treated samples are compared directly with matched controls. By generating normalised treated-to-control ratios at identical genomic positions, endogenous background breaks can be separated from treatment-associated signals. This step materially improves signal discrimination and reduces false prioritisation.

From there, quantitative and statistical modelling is applied to nominate a subset of high-confidence induced break sites from the thousands detected. Rather than presenting users with an undifferentiated catalogue, the platform produces a prioritised and defensible shortlist suitable for downstream validation or regulatory assessment.

The emphasis is not simply on finding breaks, but on ranking them in a way that supports confident decision-making.

Designed for accessibility without sacrificing depth

One of the persistent tensions in bioinformatics is accessibility versus analytical sophistication. Powerful pipelines often require command-line execution, parameter tuning, and cluster management. This places analysis in the hands of a small number of specialists and can create dependency bottlenecks within growing teams.

��ٱ��䷡-��® Analysis addresses this by integrating compute and interface within a single platform. Analyses are launched through a browser-based graphical interface, and cloud resources are provisioned on demand. From FASTQ upload to interactive report, processing typically completes in under two hours.

This removes the need for local infrastructure, pipeline maintenance, or specialist compute configuration. At the same time, detailed tabular outputs remain available for data scientists who require deeper interrogation.

The goal is not to simplify the science. It is to remove unnecessary operational friction.

Shortening the path from experiment to decision

As gene editing programs advance toward clinical translation, timelines tighten and expectations rise. Off-target data must be robust, reproducible, and clearly interpretable. Regulatory discussions demand defensible prioritisation rather than raw detection counts.

By tightly integrating assay chemistry with a purpose-built analytical engine, ��ٱ��䷡-��® Analysis shortens interpretation timelines from weeks to days. More importantly, it reduces ambiguity. Teams can move from genome-wide detection to structured nomination without relying on fragmented toolchains or manual filtering cycles.

In an environment where gene editing platforms continue to evolve, analytical clarity is no longer optional. It is foundational.

Detection will continue to improve. Sensitivity will increase. Throughput will expand.

But without integrated, decision-focused bioinformatics, more data does not mean better decisions.

And in translational gene editing, decisions are what matter.